|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carmichael J, Wing-san Mak D and O Brien
M: A review of recent advances in the treatment of elderly and poor
performance NSCLC. Cancers (Basel). 10(E236)2018.PubMed/NCBI
|
|
3
|
Nagano T, Tachihara M and Nishimura Y:
Mechanism of resistance to epidermal growth factor
receptor-tyrosine kinase inhibitors and a potential treatment
strategy. Cells. 7(E212)2018.PubMed/NCBI
|
|
4
|
Cooper MR, Alrajhi AM and Durand CR: Role
of immune checkpoint inhibitors in small cell lung cancer. Am J
Ther. 25:e349–e356. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L,
Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al: Epidermal growth
factor receptor mutations and their correlation with gefitinib
therapy in patients with non-small cell lung cancer: A
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maheswaran S, Sequist LV, Nagrath S, Ulkus
L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ,
Bell DW, et al: Detection of mutations in EGFR in circulating
lung-cancer cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou J, Greystoke A, Lancashire L, Cummings
J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, et al:
Evaluation of circulating tumor cells and serological cell death
biomarkers in small cell lung cancer patients undergoing
chemotherapy. Am J Pathol. 175:808–816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H and Durbin R: Fast and accurate short
read alignment with burrows-wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H and Durbin R: Fast and accurate
long-read alignment with burrows-wheeler transform. Bioinformatics.
26:589–595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parkinson DR, Dracopoli N, Petty BG,
Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar
P, Lee JSH, et al: Considerations in the development of circulating
tumor cell technology for clinical use. J Transl Med. 10:1382012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alix-Panabières C and Pantel K: Challenges
in circulating tumour cell research. Nat Rev Cancer. 14:623–631.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Went PT, Lugli A, Meier S, Bundi M,
Mirlacher M, Sauter G and Dirnhofer S: Frequent EpCam protein
expression in human carcinomas. Hum Pathol. 35:122–128. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Broers JL, Ramaekers FC, Rot MK,
Oostendorp T, Huysmans A, van Muijen GN, Wagenaar SS and Vooijs GP:
Cytokeratins in different types of human lung cancer as monitored
by chain-specific monoclonal antibodies. Cancer Res. 48:3221–3229.
1988.PubMed/NCBI
|
|
16
|
O Flaherty JD, Gray S, Richard D, Fennell
D, O Leary JJ, Blackhall FH and O Byrne KJ: Circulating tumour
cells, their role in metastasis and their clinical utility in lung
cancer. Lung Cancer. 76:19–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Punnoose EA, Atwal SK, Spoerke JM, Savage
H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS and
Lackner MR: Molecular biomarker analyses using circulating tumor
cells. PLoS One. 5:e125172010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tanaka F, Yoneda K, Kondo N, Hashimoto M,
Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T,
et al: Circulating tumor cell as a diagnostic marker in primary
lung cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou J, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thress KS, Brant R, Carr TH, Dearden S,
Jenkins S, Brown H, Hammett T, Cantarini M and Barrett JC: EGFR
mutation detection in ctDNA from NSCLC patient plasma: A
cross-platform comparison of leading technologies to support the
clinical development of AZD9291. Lung Cancer. 90:509–515. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bordi P, Del Re M, Danesi R and Tiseo M:
Circulating DNA in diagnosis and monitoring EGFR gene mutations in
advanced non-small cell lung cancer. Transl Lung Cancer Res.
4:584–597. 2015.PubMed/NCBI
|
|
23
|
Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang
F, Xu L and Yin R: Circulating tumor DNA is effective for the
detection of EGFR mutation in non-small cell lung cancer: A
meta-analysis. Cancer Epidemiol Biomarkers Prev. 24:206–212. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jahr S, Hentze H, Englisch S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.PubMed/NCBI
|
|
25
|
Alix-Panabières C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Effenberger KE, Schroeder C, Eulenburg C,
Reeh M, Tachezy M, Riethdorf S, Vashist YK, Izbicki JR, Pantel K
and Bockhorn M: Disseminated tumor cells in pancreatic cancer-an
independent prognosticator of disease progression and survival. Int
J Cancer. 131:E475–E483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gorges TM, Penkalla N, Schalk T, Joosse
SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta
N, et al: Enumeration and molecular characterization of tumor cells
in lung cancer patients using a novel in vivo device for capturing
circulating tumor cells. Clin Cancer Res. 22:2197–2206. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marchetti A, Del Grammastro M, Felicioni
L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A,
Brandes AA, et al: Assessment of EGFR mutations in circulating
tumor cell preparations from NSCLC patients by next generation
sequencing: Toward a real-time liquid biopsy for treatment. PLoS
One. 9:e1038832014. View Article : Google Scholar : PubMed/NCBI
|
